Literature DB >> 30263933

The role of polycomb repressive complex 2 in early T-cell precursor acute lymphoblastic leukemia.

Kathrin M Bernt1,2, Tobias Neff1,2.   

Abstract

Genetic lesions affecting polycomb repressive complex 2 (PRC2) have been found in more than 40% of pediatric cases of early T-cell precursor acute lymphoblastic leukemia. The functional role of these PRC2 alterations has been obscure. Our recent data suggest that compromise of PRC2 blocks differentiation and accentuates growth and survival signaling.

Entities:  

Year:  2018        PMID： 30263933      PMCID： PMC6154862          DOI： 10.1080/23723556.2016.1166309

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

Review 1.  Transcriptional regulation by Polycomb group proteins.

Authors:  Luciano Di Croce; Kristian Helin
Journal:  Nat Struct Mol Biol       Date:  2013-10       Impact factor: 15.369

2.  Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.

Authors:  Shannon L Maude; Sibasish Dolai; Cristina Delgado-Martin; Tiffaney Vincent; Alissa Robbins; Arthavan Selvanathan; Theresa Ryan; Junior Hall; Andrew C Wood; Sarah K Tasian; Stephen P Hunger; Mignon L Loh; Charles G Mullighan; Brent L Wood; Michelle L Hermiston; Stephan A Grupp; Richard B Lock; David T Teachey
Journal:  Blood       Date:  2015-02-02       Impact factor: 22.113

3.  A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia.

Authors:  Camille Simon; Jalila Chagraoui; Jana Krosl; Patrick Gendron; Brian Wilhelm; Sébastien Lemieux; Geneviève Boucher; Pierre Chagnon; Simon Drouin; Raphaëlle Lambert; Claude Rondeau; Annie Bilodeau; Sylvie Lavallée; Martin Sauvageau; Josée Hébert; Guy Sauvageau
Journal:  Genes Dev       Date:  2012-03-19       Impact factor: 11.361

4.  Polycomb repressive complex 2 is required for MLL-AF9 leukemia.

Authors:  Tobias Neff; Amit U Sinha; Michael J Kluk; Nan Zhu; Mohamed H Khattab; Lauren Stein; Huafeng Xie; Stuart H Orkin; Scott A Armstrong
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-06       Impact factor: 11.205

5.  PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies.

Authors:  Thomas De Raedt; Eline Beert; Eric Pasmant; Armelle Luscan; Hilde Brems; Nicolas Ortonne; Kristian Helin; Jason L Hornick; Victor Mautner; Hildegard Kehrer-Sawatzki; Wade Clapp; James Bradner; Michel Vidaud; Meena Upadhyaya; Eric Legius; Karen Cichowski
Journal:  Nature       Date:  2014-08-13       Impact factor: 49.962

6.  The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.

Authors:  Jinghui Zhang; Li Ding; Linda Holmfeldt; Gang Wu; Sue L Heatley; Debbie Payne-Turner; John Easton; Xiang Chen; Jianmin Wang; Michael Rusch; Charles Lu; Shann-Ching Chen; Lei Wei; J Racquel Collins-Underwood; Jing Ma; Kathryn G Roberts; Stanley B Pounds; Anatoly Ulyanov; Jared Becksfort; Pankaj Gupta; Robert Huether; Richard W Kriwacki; Matthew Parker; Daniel J McGoldrick; David Zhao; Daniel Alford; Stephen Espy; Kiran Chand Bobba; Guangchun Song; Deqing Pei; Cheng Cheng; Stefan Roberts; Michael I Barbato; Dario Campana; Elaine Coustan-Smith; Sheila A Shurtleff; Susana C Raimondi; Maria Kleppe; Jan Cools; Kristin A Shimano; Michelle L Hermiston; Sergei Doulatov; Kolja Eppert; Elisa Laurenti; Faiyaz Notta; John E Dick; Giuseppe Basso; Stephen P Hunger; Mignon L Loh; Meenakshi Devidas; Brent Wood; Stuart Winter; Kimberley P Dunsmore; Robert S Fulton; Lucinda L Fulton; Xin Hong; Christopher C Harris; David J Dooling; Kerri Ochoa; Kimberly J Johnson; John C Obenauer; William E Evans; Ching-Hon Pui; Clayton W Naeve; Timothy J Ley; Elaine R Mardis; Richard K Wilson; James R Downing; Charles G Mullighan
Journal:  Nature       Date:  2012-01-11       Impact factor: 49.962

7.  EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.

Authors:  Wendy Béguelin; Relja Popovic; Matt Teater; Yanwen Jiang; Karen L Bunting; Monica Rosen; Hao Shen; Shao Ning Yang; Ling Wang; Teresa Ezponda; Eva Martinez-Garcia; Haikuo Zhang; Yupeng Zheng; Sharad K Verma; Michael T McCabe; Heidi M Ott; Glenn S Van Aller; Ryan G Kruger; Yan Liu; Charles F McHugh; David W Scott; Young Rock Chung; Neil Kelleher; Rita Shaknovich; Caretha L Creasy; Randy D Gascoyne; Kwok-Kin Wong; Leandro Cerchietti; Ross L Levine; Omar Abdel-Wahab; Jonathan D Licht; Olivier Elemento; Ari M Melnick
Journal:  Cancer Cell       Date:  2013-05-13       Impact factor: 31.743

8.  Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network.

Authors:  Aurélie Caye; Marion Strullu; Fabien Guidez; Bruno Cassinat; Steven Gazal; Odile Fenneteau; Elodie Lainey; Kazem Nouri; Saeideh Nakhaei-Rad; Radovan Dvorsky; Julie Lachenaud; Sabrina Pereira; Jocelyne Vivent; Emmanuelle Verger; Dominique Vidaud; Claire Galambrun; Capucine Picard; Arnaud Petit; Audrey Contet; Marilyne Poirée; Nicolas Sirvent; Françoise Méchinaud; Dalila Adjaoud; Catherine Paillard; Brigitte Nelken; Yves Reguerre; Yves Bertrand; Dieter Häussinger; Jean-Hugues Dalle; Mohammad Reza Ahmadian; André Baruchel; Christine Chomienne; Hélène Cavé
Journal:  Nat Genet       Date:  2015-10-12       Impact factor: 38.330

9.  Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential.

Authors:  Louise M Treanor; Sheng Zhou; Laura Janke; Michelle L Churchman; Zhijun Ma; Taihe Lu; Shann-Ching Chen; Charles G Mullighan; Brian P Sorrentino
Journal:  J Exp Med       Date:  2014-03-31       Impact factor: 14.307

10.  Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia.

Authors:  Etienne Danis; Taylor Yamauchi; Kristen Echanique; Xi Zhang; Jessica N Haladyna; Simone S Riedel; Nan Zhu; Huafeng Xie; Stuart H Orkin; Scott A Armstrong; Kathrin M Bernt; Tobias Neff
Journal:  Cell Rep       Date:  2016-02-18       Impact factor: 9.423
  10 in total
  1 in total

1.  JAK/BCL2 inhibition acts synergistically with LSD1 inhibitors to selectively target ETP-ALL.

Authors:  Aissa Benyoucef; Katharina Haigh; Andrew Cuddihy; Jody J Haigh
Journal:  Leukemia       Date:  2022-10-13       Impact factor: 12.883
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.